Triple play ends
Stockholm/Leiden/Barcelona – A complicated ménage a trois has come to an end: Swedish Orphan Biovitrum AB, Pharming Group N.V. and Esteve S.A. announced at the beginning of September that they were terminating a 2004 deal involving the drug Ruconest®. According to the terms of the agreement, Esteve received exclusive rights from Pharming to commercialise the hereditary angioedema treatment in Spain, Portugal, Andorra and Greece. Pharming has now granted those rights to Swedish Orphan, making it the sole distributor of the recombinant human complement 1 (C1) esterase inhibitor in all EU countries, Iceland, Norway, Switzerland, the Balkans, North Africa and the Middle East. Ruconest is approved for the indication in the EU. Further details were not disclosed.